ArticleScientific reports2025
In silico evaluation of the anti Helicobacter pylori activity of selected bioactive compounds from Aloe vera.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori causes peptic ulcer, which is estimated to affect about half of the human population. Current treatments present with adverse side effects, and increasing antibiotic resistance have intensified the search for alternative therapeutic agents.
aimThis study explores the inhibitory potential of selected bioactive compounds of Aloe vera against H. pylori neutrophil-activating protein (NAP) using an in-silico approach.
methodsMolecular docking, simulation (300 ns), ADMET (absorption, distribution, metabolism, excretion and transportation) predictions and density function theory (DFT) were carried out using standard protocols with the co-crystal or native ligand used as control.
resultsDocking results identified aloesin as the top candidate (-7.4 kcal/mol), followed by aloe-emodin and chrysophanic acid (-6.4 kcal/mol) and esculetin (-6.3 kcal/mol), all outperforming the control ligand (-4.3 kcal/mol). Key receptor-ligand interactions involved amino acids residues, including Ser135, Glu46, and Tyr99, essential for binding stability. Molecular dynamics simulations confirmed complex stability, with RMSD values ≤ 4 Å. RMSF analysis highlighted fluctuations at residues 30, 80/85, and 140, while contact analysis revealed the significance of water bridges and hydrogen bonds. ADMET profiling revealed that all the ligands complied with the Lipinski rule of five and exhibited high intestinal absorption values. Our ranking of the ligands using the docking affinities and RMSD values showed that chrysophanic acid and esculetin were the best ligands. The DFT evaluation showed that esculetin was the most reactive of all the ligands indicated by its least energy score. These findings suggest that aloesin, chrysophanic acid and esculetin could serve as promising alternatives for H. pylori treatment. However, further in vitro and in vivo studies are needed to validate their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.